| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 32.87 | 2034 |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
BeyondSpring Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company pioneering innovative cancer therapies. Headquartered in New York, the company focuses on developing Plinabulin, a novel immune-modulating microtubule-binding agent with applications in chemotherapy-induced neutropenia (CIN) and non-small cell lung cancer (NSCLC). Plinabulin has completed Phase III trials for CIN prevention and late-stage NSCLC treatment, positioning BeyondSpring as a potential disruptor in oncology. The company is also exploring combination therapies with immuno-oncology agents like PD-1/PD-L1 inhibitors, aiming to enhance treatment efficacy across multiple cancer types. With a robust preclinical pipeline of small-molecule immune agents and a proprietary drug development platform, BeyondSpring targets high-unmet-need areas in oncology. Operating in the $200B+ global oncology market, the company's success hinges on clinical validation and regulatory approvals for its lead candidate.
BeyondSpring presents a high-risk, high-reward opportunity for biotech investors. The company's valuation hinges almost entirely on Plinabulin's clinical and regulatory success, with no current revenue and negative EPS (-$0.28). Positive Phase III data for CIN could create near-term catalysts, but the $68M market cap reflects significant clinical and commercialization risks. The ultra-low beta (0.125) suggests minimal correlation with broader markets, typical of developmental biotechs. With $2.9M cash and consistent operating cash burn (-$16.4M), additional financing may be required ahead of potential commercialization. Investors should monitor: 1) FDA interactions regarding Plinabulin's NDA submission, 2) partnership announcements for commercialization, and 3) data readouts from combination therapy trials.
BeyondSpring competes in two distinct but overlapping spaces: CIN prophylaxis and NSCLC treatment. In CIN, Plinabulin aims to challenge Neulasta (Amgen's pegfilgrastim), the $4B+ market leader, by offering potentially superior safety (reduced bone pain) and immune-enhancing effects. However, biosimilar competition has eroded Neulasta's pricing power, creating reimbursement challenges for new entrants. In NSCLC, Plinabulin's differentiation lies in its dual mechanism (immune modulation + vascular disruption) when combined with PD-1 inhibitors, but it faces entrenched competitors like Keytruda and Opdivo. BeyondSpring's key advantages include: 1) Plinabulin's novel mechanism that may avoid granulocyte colony-stimulating factor (G-CSF) limitations, 2) oral administration potential versus injectable competitors, and 3) synergistic potential with checkpoint inhibitors. However, the company lacks commercial infrastructure and will likely need partnerships to compete with large-cap oncology players. Its $68M valuation suggests the market remains skeptical about Plinabulin's commercial potential relative to late-stage development risks.